[APPswe/PS1dE9/Blg Transgenic Mouse Line for Modeling Cerebral Amyloid Angiopathy Associated with Alzheimer's Disease]. 2023

E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432 Russia.

Alzheimer's disease (AD) is the most common proteinopathy, which is accompanied by a steady decrease in the patient's cognitive functions with a simultaneous accumulation of amyloid plaques in brain tissues. Amyloid plaques are extracellular aggregates of amyloid β (Aβ) and are associated with neuroinflammation and neurodegeneration. Unlike humans and all other mammals, rats and mice do not reproduce AD-like pathology because there are three amino acid substitutions in their Aβ. Amyloid plaques form in the brains of transgenic mice with overexpression of human Aβ, and such mice are therefore possible to use in biomedicine to model the key features of AD. The transgenic mouse line APPswe/PS1dE9 is widely used as an animal model to study the molecular mechanisms of AD. A study was made to characterize the APPswe/PS1dE9/Blg subline, which was obtained by crossing APPswe/PS1dE9 mice on a CH3 genetic background with C57Bl6/Chg mice. No difference in offspring's survival and fertility was observed in the subline compared to wild-type control mice. Histological analysis of the brain in the APPswe/PS1dE9/Blg line confirmed the main neuromorphological features of AD and showed that amyloid plaques progressively increase in number and size during aging. The APPswe/PS1dE9/Blg line was assumed to provide a convenient model for developing therapeutic strategies to slow down AD progression.

UI MeSH Term Description Entries
D008322 Mammals Warm-blooded vertebrate animals belonging to the class Mammalia, including all that possess hair and suckle their young. Mammalia,Mammal
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid
D016657 Cerebral Amyloid Angiopathy A heterogeneous group of sporadic or familial disorders characterized by AMYLOID deposits in the walls of small and medium sized blood vessels of CEREBRAL CORTEX and MENINGES. Clinical features include multiple, small lobar CEREBRAL HEMORRHAGE; cerebral ischemia (BRAIN ISCHEMIA); and CEREBRAL INFARCTION. Cerebral amyloid angiopathy is unrelated to generalized AMYLOIDOSIS. Amyloidogenic peptides in this condition are nearly always the same ones found in ALZHEIMER DISEASE. (from Kumar: Robbins and Cotran: Pathologic Basis of Disease, 7th ed., 2005) Amyloid Angiopathy, Cerebral,Congophilic Angiopathy,Sporadic Cerebral Amyloid Angiopathy,Angiopathy, Cerebral Amyloid,Angiopathy, Congophilic,Cerebral Amyloid Angiopathies,Congophilic Angiopathies
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
December 2009, Current Alzheimer research,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
January 2020, Behavioural neurology,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
May 2016, Journal of Alzheimer's disease : JAD,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
August 2011, Neuroscience bulletin,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
January 2021, Journal of Alzheimer's disease : JAD,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
January 2001, Advances in experimental medicine and biology,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
December 1993, Internal medicine (Tokyo, Japan),
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
February 2014, The Journal of nutritional biochemistry,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
July 2010, Hirosaki igaku = Hirosaki medical journal,
E A Lysikova, and E V Kuzubova, and A I Radchenko, and E A Patrakhanov, and K D Chaprov, and M V Korokin, and A V Deykin, and O S Gudyrev, and M V Pokrovskii
January 2008, International journal of clinical and experimental pathology,
Copied contents to your clipboard!